ATTAIN STUDY ACLIDINIUM PDF

Aclidinium Bromid mug verbesserte in der Milara, E. Garbarda, A. Gavalda, M. Miralpeix, J. Beleta, E.

Author:Akikazahn Brasho
Country:Germany
Language:English (Spanish)
Genre:Literature
Published (Last):23 June 2014
Pages:463
PDF File Size:15.46 Mb
ePub File Size:16.23 Mb
ISBN:721-1-85339-192-3
Downloads:59610
Price:Free* [*Free Regsitration Required]
Uploader:Dougal



However, only the results from the ATTAIN study, which was powered to detect a treatment difference in these endpoints are discussed here. Rate ratios were 0. The rate of moderate to severe exacerbations needing treatment with antibiotics or corticosteroids or resulting in hospitalisation was not statistically significantly reduced with aclidinium bromide.

These studies did not have the statistical power to detect a difference in exacerbations, and these results need to be confirmed in further trials. Safety The percentage of patients reporting adverse events was similar between all groups in both studies.

These percentages were The studies did not state whether there were statistically significant differences between groups in these events. In both studies, the incidence of anticholinergic-related adverse effects for example, dry mouth and constipation was low and similar across groups. Patients with unstable cardiac conditions were excluded from the studies, and these conditions may be affected by the anticholinergic mechanism of action of aclidinium bromide.

Evidence strengths and limitations Both studies demonstrate that aclidinium bromide has beneficial effects on lung function in people with moderate to severe COPD. However, the studies had several limitations that affect their usefulness in assessing the place in therapy of aclidinium bromide within the NHS. Both studies also reported on COPD exacerbations. However, the publication of further longer term studies designed to measure these outcomes and assess long-term safety would be useful. Secondly, the comparator in these studies was placebo.

Results from studies comparing aclidinium bromide with an active comparator on clinically important outcomes, such as COPD exacerbations, would enable its place in therapy to be more clearly established. Patients in these trials had moderate to severe COPD; no published data are available on patients with mild or very severe disease.

For both studies allocation concealment was unclear, which may have introduced bias.

ANALISE FINANCEIRA DE BALANOS MATARAZZO PDF

Chronic obstructive pulmonary disease: aclidinium bromide

However, only the results from the ATTAIN study, which was powered to detect a treatment difference in these endpoints are discussed here. Rate ratios were 0. The rate of moderate to severe exacerbations needing treatment with antibiotics or corticosteroids or resulting in hospitalisation was not statistically significantly reduced with aclidinium bromide. These studies did not have the statistical power to detect a difference in exacerbations, and these results need to be confirmed in further trials. Safety The percentage of patients reporting adverse events was similar between all groups in both studies. These percentages were

ELOISA JAMES FOOL FOR LOVE PDF

Aclidinium (Bretaris Genuair) for chronic obstructive pulmonary disease

Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. This article has been cited by other articles in PMC. Abstract Three long-acting muscarinic antagonists LAMAs are now available in Europe, providing clinicians and patients with a choice of interventions, which is important in COPD, which is clinically a heterogeneous disease. Another new once-daily LAMA, glycopyrronium, has also been shown to improve health status and reduce exacerbations, and is well tolerated.

HAYEK DENATIONALISATION OF MONEY PDF

Clinical use of aclidinium in patients with COPD

.

ENTS OF FANGORN PDF

Efficacy in COPD

.

Related Articles